Cardiac ischemia-reperfusion: The heart is one of the tissues where EPOs tissue-protective effects were first documented, and the IRR is expressed in cardiac tissue
These advanced treatments target the root causes of imbalance, supporting energy, metabolism, cognitive health, and overall longevity
Similarly, TB-500 has undergone extensive safety evaluation including human research trials showing safety at intravenous doses up to 1,260 mg equivalent, with no dose-limiting toxicities or serious adverse events attributable to the peptide in carefully controlled studies
Appetite Suppression : Activation of the GLP-1 receptor in the brain can lead to a reduction in appetite and food intake, aiding in weight loss
AOD-9604 is sold for research purposes only and is not FDA-approved for human therapeutic use
References: Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R